• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[18F]NaF PET/CT 扫描作为进行性骨化性纤维发育不良中异位骨化的早期标志物。

[18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.

机构信息

Department of Internal Medicine Section Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.

Department of Internal Medicine Section Endocrinology, VU University Medical Center, Amsterdam, The Netherlands.

出版信息

Bone. 2018 Apr;109:143-146. doi: 10.1016/j.bone.2017.08.012. Epub 2017 Aug 18.

DOI:10.1016/j.bone.2017.08.012
PMID:28826841
Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease with a progressive course characterized by episodically local flare-ups, which often but not always leads to heterotopic bone formation (HO). Recently, we showed that [18F]NaF PET/CT may be the first tool to monitor progression of a posttraumatic flare-up leading to new HO, which was demonstrated in a patient with FOP who underwent a maxillofacial surgery. This paper evaluates [18F]NaF PET/CT as a marker of FOP disease activity, comparing its use with other imaging modalities known in literature. In addition, the follow-up of a spontaneous flare-up in a 19-year old patient is presented showing high muscle [18F]NaF uptake in one defined part within the flare-up area after three weeks. During follow-up [18F]NaF PET /CT scan revealed newly formed heterotopic bone but only in this previously active [18F]NaF region. In conclusion, increased muscle [18F]NaF uptake may predict future HO development in FOP patients. At present [18F]NaF PET/CT appears to be a sensitive imaging modality to serve as a noninvasive marker for bone formation and to monitor disease activity during flare-ups in FOP.

摘要

进行性骨化性纤维发育不良(FOP)是一种罕见的遗传性疾病,具有进行性病程,其特征为间歇性局部发作,通常但并非总是导致异位骨形成(HO)。最近,我们表明[18F]NaF PET/CT 可能是监测导致新 HO 的创伤后发作进展的第一个工具,在接受颌面外科手术的 FOP 患者中得到了证实。本文评估了[18F]NaF PET/CT 作为 FOP 疾病活动的标志物,将其与文献中已知的其他成像方式进行了比较。此外,还介绍了一名 19 岁患者自发性发作的随访情况,显示在发作后 3 周,发作区域内一个明确部位的肌肉[18F]NaF 摄取量增加。在随访期间,[18F]NaF PET/CT 扫描显示新形成的异位骨,但仅在先前活跃的[18F]NaF 区域。总之,肌肉[18F]NaF 摄取增加可能预示 FOP 患者未来发生 HO。目前,[18F]NaF PET/CT 似乎是一种敏感的成像方式,可作为骨形成的非侵入性标志物,并在 FOP 发作期间监测疾病活动。

相似文献

1
[18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.[18F]NaF PET/CT 扫描作为进行性骨化性纤维发育不良中异位骨化的早期标志物。
Bone. 2018 Apr;109:143-146. doi: 10.1016/j.bone.2017.08.012. Epub 2017 Aug 18.
2
Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: An [F]NaF PET/CT study.纤维性骨发育不良性骨化性肌炎中异位骨的演变:一项[F]NaF PET/CT 研究。
Bone. 2019 Jul;124:1-6. doi: 10.1016/j.bone.2019.03.009. Epub 2019 Mar 8.
3
Flare-Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [F]-NaF PET/CT Study and a Systematic Review.进行性骨化性纤维发育不良患者颌面外科手术后的病情复发:一项[F]-NaF PET/CT研究及系统评价
JBMR Plus. 2017 Jul 5;2(1):55-58. doi: 10.1002/jbm4.10008. eCollection 2018 Jan.
4
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial.成纤维细胞性骨化发育不良成人患者flare-ups 的特征及 garetosmab 的影响:LUMINA-1 试验的一项随机、双盲、安慰剂对照的事后分析。
J Bone Miner Res. 2024 Sep 26;39(10):1486-1492. doi: 10.1093/jbmr/zjae140.
5
Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.纤维性骨发育不良进展性的影像学评估:定性、定量和可疑。
Bone. 2018 Apr;109:147-152. doi: 10.1016/j.bone.2017.08.011. Epub 2017 Aug 16.
6
Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature.成骨不全性骨纤维结构不良的放射治疗:病例报告和文献系统评价。
Front Endocrinol (Lausanne). 2020 Feb 12;11:6. doi: 10.3389/fendo.2020.00006. eCollection 2020.
7
The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.纤维性骨发育不良性骨生成过度中的异位骨形成是激活素 A 依赖性的。
J Bone Miner Res. 2017 Dec;32(12):2489-2499. doi: 10.1002/jbmr.3235. Epub 2017 Sep 22.
8
Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.大多数纤维性骨发育不良性骨化性肌炎患者的骨折经非手术治疗后愈合,且很少出现发作、异位骨化和活动度丧失。
Clin Orthop Relat Res. 2023 Dec 1;481(12):2447-2458. doi: 10.1097/CORR.0000000000002672. Epub 2023 May 8.
9
Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良中异位骨的X线评估模拟方法
Acad Radiol. 2017 Mar;24(3):321-327. doi: 10.1016/j.acra.2016.10.010. Epub 2016 Dec 15.
10
A fibrodysplasia ossificans progressiva patient with a rare missense mutation in ACVR1 detected on F-FDG PET/CT.成纤维细胞发育不良性骨化性纤维瘤病患者在 F-FDG PET/CT 上检测到 ACVR1 罕见错义突变。
Joint Bone Spine. 2024 Mar;91(2):105682. doi: 10.1016/j.jbspin.2023.105682. Epub 2023 Dec 29.

引用本文的文献

1
F-NaF PET/CT identifies muscular and subcutaneous calcifications in both dermatomyositis- and systemic sclerosis-related calcinosis.F-NaF PET/CT可识别皮肌炎和系统性硬化症相关钙质沉着症中的肌肉和皮下钙化。
Front Nucl Med. 2025 May 30;5:1593825. doi: 10.3389/fnume.2025.1593825. eCollection 2025.
2
A mouse model of Jansen's metaphyseal chondrodysplasia for investigating disease mechanisms and candidate therapeutics.用于研究疾病机制和候选治疗方法的詹森干骺端软骨发育不良小鼠模型。
Proc Natl Acad Sci U S A. 2025 Jun 10;122(23):e2500176122. doi: 10.1073/pnas.2500176122. Epub 2025 Jun 2.
3
Challenges and advances in the management of heterotopic ossification in total hip arthroplasty.
全髋关节置换术中异位骨化管理的挑战与进展
Bone Joint Res. 2025 Apr 16;14(4):351-355. doi: 10.1302/2046-3758.144.BJR-2024-0323.R1.
4
[F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders.氟[18F]去铁胺 PET/CT 作为成骨不全性骨纤维发育异常的标志物:从分子机制到骨骼疾病的临床应用。
Biomolecules. 2024 Oct 10;14(10):1276. doi: 10.3390/biom14101276.
5
Performance of simplified methods for quantification of [F]NaF uptake in fibrodysplasia ossificans progressiva.进行性骨化性纤维发育不良中[F]氟化钠摄取定量简化方法的性能
Front Nucl Med. 2024 Jul 22;4:1406947. doi: 10.3389/fnume.2024.1406947. eCollection 2024.
6
Utility of a simplified [F] sodium fluoride PET imaging method to quantify bone metabolic flux for a wide range of clinical applications.简化 [F] 氟化钠 PET 成像方法在广泛的临床应用中定量评估骨代谢通量的效用。
Front Endocrinol (Lausanne). 2023 Sep 13;14:1236881. doi: 10.3389/fendo.2023.1236881. eCollection 2023.
7
Pediatric Heterotopic Ossification: A Comprehensive Review.小儿异位骨化:全面综述
Curr Rev Musculoskelet Med. 2023 Nov;16(11):514-520. doi: 10.1007/s12178-023-09862-y. Epub 2023 Aug 17.
8
Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography.应用家庭式电阻抗肌图评估进行性骨化性纤维发育不良患者的肌肉完整性受损。
Sci Rep. 2022 Dec 3;12(1):20908. doi: 10.1038/s41598-022-25610-7.
9
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).方案论文:一项多中心、双盲、随机、6 个月、安慰剂对照研究,随后进行 12 个月的开放标签扩展,以评估 Saracatinib 在纤维发育不良性骨化进展症(STOPFOP)中的安全性和疗效。
BMC Musculoskelet Disord. 2022 Jun 1;23(1):519. doi: 10.1186/s12891-022-05471-x.
10
Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives.进行性骨化性纤维发育不良的监测与管理:当前观点
Orthop Res Rev. 2022 Apr 20;14:113-120. doi: 10.2147/ORR.S337491. eCollection 2022.